«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

25卷

期数:

2019年01期

页码:

51-53

栏目:

临床医学

出版日期:

2019-01-20

文章信息/Info

Title:

The relationship between expression of RRM1 mRNA and efficacy of intravesical of gemcitabine in patients with nonmuscle-insive bladder caner

文章编号:

1006-8147(2019)01-0051-03

作者:

刘志飞¹; 2; 张志宏¹; 邢力永²; 朱研峰²; 石 鹏²; 邓 刚²

（1．天津医科大学第二医院泌尿外科，天津市泌尿外科研究所，天津300211；2. 唐山市人民医院泌尿外科，唐山063000）

Author(s):

LIU Zhi-fei¹; 2;  ZHANG Zhi-hong¹;  XING Li-yong²;  ZHU Yan-feng²;  SHI Peng²;  DENG Gang²

（1.Department of Urology，The Second Hospital, Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China；2.Department of Urology，Tangshan People’s Hospital, Tangshan 063000, China）

关键词:

RRM1; 膀胱癌; 液相芯片技术

Keywords:

RRM1;  bladder caner;  liquid-chip technology

分类号:

R737.14

DOI:

-

文献标志码:

A

摘要:

目的：研究分析RRM1 mRNA在膀胱癌患者中的表达及其与吉西他滨药物膀胱灌注化疗效果敏感性的关系，旨在为临床膀胱癌患者术后辅助化疗提供个体化治疗方案。方法：采用液相芯片技术检测RRM1 mRNA在膀胱癌患者中的表达， 并分析其临床意义。结果：RRM1 mRNA 在高级别膀胱尿路上皮癌患者中呈现高表达为12例（30%），呈现低表达为6例（15%）；在低级别尿路上皮癌患者中高表达为4例（10%），低表达为18例（45%）；应用吉西他滨药物膀胱灌注的膀胱癌患者术后随访1年，其中RRM1 mRNA低表达的患者复发1例（2.5%），RRM1 mRNA高表达的患者复发5例（12.5%）。结论：RRM1 mRNA在膀胱癌患者中的表达与肿瘤病理分级呈正相关关系。RRM1 mRNA表达与吉西他滨膀胱灌注辅助化疗药物敏感性呈负相关关系。RRM1 mRNA在膀胱癌患者中的表达对膀胱癌患者术后辅助化疗药物的选择具有重要指导意义。

Abstract:

Objective: To explore and analysis the expression of RRM1 mRNA and the relationship of gemcitabine intravesical chemotherapy in patients with bladder caner. Methods：We detected the expression levels of RRM1 mRNA in NMIBC by the branch DNA-chip technology and assessed the association between T RRM1 mRNA levels and the efficacy of gemcitabine. Results： Of the 40 patients, 12 (30%) had high expression levels of RRM1 mRNA in high grade bladder urothelial carcinoma, and 6 (15%) participants had low levels. Four (10%) had high levels of expression levels of RRM1 mRNA in low-grade bladder urothelial carcinoma, and 18(45%) participants had low levels. In bladder cancer patients with anthracycline intravesical postoperative follow-up of one year, 1 case(2.5%)ofrecurrence of the RRM1 mRNA low expression of was found, 5 cases(12.5%)of recurrence of RRM1 mRNA high expression were found. The mRNA expression level of RRM1 was more significantlyassociated with high-grade tumor than with patients with low-grade tumors(P<0.05). The expression levels of RRM1 mRNA showed a strong negative correlation with the efficacy of intravesical gemcitabine (P <0.05). Conclusion：RRM1 mRNA expression and tumor grade in bladder cancer patients may have a positive correlation. And RRM1 mRNA and gemcitabine sensitivity are positively correlated. RRM1 mRNA expression in bladder cancer patients has important guiding significance in the selection of drug in adjuvant chemotherapy for bladder cancer patients.

参考文献/References:

[1] Matsumura N, Kusumoto H, Sasaki Y, et al. 1893 the significance of combined analysis of human equilibrative nucleoside transporter 1(HENT1)and ribonucleotide reductase M1(RRM1)in advanced bladder cancer patients with gemcitabine-based chemotherapy[J]. J Urol, 2012, 187(4):e763
[2] 南勇. 羟基喜树碱与吡柔比星膀胱灌注预防非肌层浸润性膀胱癌术后复发的疗效比较[J]. 海南医学, 2014(23):113
[3] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(1):10
[4] Leopardo D, Cecere S C, Di Napoli M, et al. Intravesical chemo-immunotherapy in non muscle invasive bladder cancer[J]. Eur Rev Med Pharmacol Sci, 2013, 17(16):2145
[5] Sarries C, Haura E B, Roig B, et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer[J]. Pharmacogenomics, 2002, 3(6):763
[6] Bergman A M, Eijk P P, Ruiz Van Haperen V W, et al. In vivo induction of resistance to Gemcitabine results in increased expression of ribonucleotide reductase subunit MI as the major determinant[J]. Cancer Res, 2005, 65(20):9510
[7] 王琪.肿瘤相关基因RRM1和TUBB3 mRNA表达水平的检测在个体化用药中的初步应用[D].西安:西北大学, 2013
[8] Mini E. Cellullar pharmacology of gemcitabine[J]. Ann Oncol,2006,17(S5):7
[9] Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and Platinum in non-small-cell lung cancer[J]. J Clin Oncol, 2006, 24(29):4731
[10] Reynolds C, Obasaju C, Schell M J, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer[J].J Clin Oncol, 2009, 27(34):5808
[11] Vilmar A C, Santoni-Rugiu E, Sorensen J. Predictive impact of RRM 1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in achemotherapy phase III trial[J]. Ann Oncol,2013,24(2):309

相似文献/References:

[1]陈可新,郝晓东,薄志强,等.≤pT2N0M0膀胱癌根治术后近期复发的影响因素分析[J].天津医科大学学报,2017,23(04):357.
　CHEN Ke-xin,HAO Xiao-dong,BO Zhi-qiang,et al.Influencing factors and prognosis of short-term relapse after radical cystectomy of primary bladder cancer（≤pT2N0M0）[J].Journal of Tianjin Medical University,2017,23(01):357.
[2]孟旭英,李珍瑾,郭剑超.组蛋白甲基转移酶EZH2抑制剂联合抗癌药物对膀胱癌细胞功能影响的研究[J].天津医科大学学报,2018,24(01):25.
　MENG Xu-ying,LI Zhen-jin,GUO Jian-chao.Effect of histone methyltransferase EZH2 inhibitor combined with anticancer drugs on migration and proliferation of bladder cancer cells[J].Journal of Tianjin Medical University,2018,24(01):25.
[3]刘 莉 康家旗 综 述,刘晓强 审 校.膀胱癌外周血生物标志物研究进展[J].天津医科大学学报,2018,24(06):566.
[4]付真睿,盛 飞,张昌文,等.SOX6在膀胱癌发生发展中的作用及相关机制[J].天津医科大学学报,2019,25(04):373.
　FU Zhen-rui,SHENG Fei,ZHANG Chang-wen,et al.The characteristics of SOX6 in development of bladder cancer and relevant mechanism[J].Journal of Tianjin Medical University,2019,25(01):373.
[5]王银蕾,杨 瀚,高 杰,等.PITX2启动子甲基化及其与膀胱癌临床病理的关系[J].天津医科大学学报,2020,26(01):39.
　WANG Yin-lei,YANG Han,GAO Jie,et al.Methylation of PITX2 promoter and relationship with clinical pathology of bladder cancer[J].Journal of Tianjin Medical University,2020,26(01):39.
[6]王玉杰,沈冲,高深,等.长链非编码RNA-FENDRR在膀胱癌组织中的表达及临床意义[J].天津医科大学学报,2020,26(05):445.
　WANG Yu-jie,SHEN Chong,GAO Shen,et al.Expression of long non-coding RNA FENDRR in human bladder cancer tissues and Clinical significance[J].Journal of Tianjin Medical University,2020,26(01):445.
[7]朱建强,郑志文,付青峰,等.人工纳米材料在膀胱癌诊疗中的研究进展[J].天津医科大学学报,2022,28(05):563.
[8]陆益,于佳熙,梁政.氯丙嗪对膀胱癌BT-B细胞迁移功能的影响[J].天津医科大学学报,2022,28(06):621.
　LU Yi,YU Jia-xi,LIANG Zheng.The effect of chlorpromazine on the migration of BT-B cellsin bladder cancer[J].Journal of Tianjin Medical University,2022,28(01):621.
[9]孙晓宇 张志宏 张昌文.膀胱癌类器官模型的研究进展[J].天津医科大学学报,2023,29(05):564.
[10]朱 亮,陈业刚.基于失巢凋亡相关标志物预测膀胱癌患者预后[J].天津医科大学学报,2024,30(01):56.[doi:10.20135/j.issn.1006-8147.2024.01.0056]
　ZHU Liang,CHEN Yegang.Prognosis of patients with bladder cancer predicted by biomarker associated with anoikis[J].Journal of Tianjin Medical University,2024,30(01):56.[doi:10.20135/j.issn.1006-8147.2024.01.0056]

备注/Memo

备注/Memo:

基金项目 河北省卫计委医学研究课题计划资助项目(20171274)
作者简介 刘志飞（1981-）男，主治医师，博士在读，研究方向：泌尿系统肿瘤；通信作者：张志宏，E-mail：zhangzhihong1202@163.com。

常用功能

更新日期/Last Update: 2019-03-01